Immunization of Human Volunteers With P. Vivax Irradiated Sporozoites

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

June 30, 2012

Primary Completion Date

May 31, 2015

Study Completion Date

September 30, 2017

Conditions
Malaria
Interventions
BIOLOGICAL

Immunization with P. vivax irradiated sporozoites

"Anopheles albimanus mosquitoes will be infected by artificial membrane feeding using blood from P. vivax infected donors. Once mosquitoes are positive will be irradiated at 15000 cGy and kept in boxes until use.~14 Fy(+) human volunteers in the experimental group will be immunized with 1,000-2,000 P. vivax irrad-spz bites. Seven Fy(+) volunteers in the control group will be exposed to non-infected mosquito bites. Six Fy(-) volunteers will be exposed to infective mosquito bites. For the challenge both the immunized and control groups will be exposed to 3 ± 1 infective mosquito bites. Volunteers will be closely monitored post infection and will be treated with antimalarials."

Trial Locations (1)

Unknown

Malaria Vaccine of Develepmente Center, Santiago de Cali

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

collaborator

Asoclinic Inmunología Ltda.

INDUSTRY

lead

Malaria Vaccine and Drug Development Center

OTHER

NCT01082341 - Immunization of Human Volunteers With P. Vivax Irradiated Sporozoites | Biotech Hunter | Biotech Hunter